DR-0201 Program (Deep B Cell Depletion)
Dren Bio’s lead platform program, DR-0201, is a first-in-class
bispecific antibody capable of
engaging tissue-resident and trafficking myeloid cells to induce deep B cell
depletion via
targeted phagocytosis. DR-0201 has demonstrated a favorable preclinical safety
profile in
multiple non-human primate studies with no cytokine release syndrome or
neurotoxicity.
DR-0201 is currently being evaluated in a Phase 1 study in B-NHL
patients and is expanding
into various autoimmune indications.
Collectively, Dren Bio’s two distinct clinical programs
represent a unique opportunity to
potentially achieve an immune reset in multiple autoimmune diseases, by inducing
deep
depletion of pathogenic B cells using DR-0201 and by selectively depleting
autoreactive CD8
cells using DR-01.